(Q51088833)

English

Relationship between progression-free survival and overall survival in patients with advanced non-small cell lung cancer treated with anticancer agents after first-line treatment failure.

scientific article published on 9 May 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 March 2018

http://europepmc.org/abstract/MED/24811212

Relationship between progression-free survival and overall survival in patients with advanced non-small cell lung cancer treated with anticancer agents after first-line treatment failure. (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 March 2018

http://europepmc.org/abstract/MED/24811212

author name string

Hidekazu Suzuki

1

1 reference

Europe PubMed Central

PubMed publication ID

29 March 2018

http://europepmc.org/abstract/MED/24811212

Tomonori Hirashima

2

1 reference

Europe PubMed Central

PubMed publication ID

29 March 2018

http://europepmc.org/abstract/MED/24811212

Norio Okamoto

3

1 reference

Europe PubMed Central

PubMed publication ID

29 March 2018

http://europepmc.org/abstract/MED/24811212

Tadahiro Yamadori

4

1 reference

Europe PubMed Central

PubMed publication ID

29 March 2018

http://europepmc.org/abstract/MED/24811212

Motohiro Tamiya

5

1 reference

Europe PubMed Central

PubMed publication ID

29 March 2018

http://europepmc.org/abstract/MED/24811212

Naoko Morishita

6

1 reference

Europe PubMed Central

PubMed publication ID

29 March 2018

http://europepmc.org/abstract/MED/24811212

Takayuki Shiroyama

7

1 reference

Europe PubMed Central

PubMed publication ID

29 March 2018

http://europepmc.org/abstract/MED/24811212

Sawa Takeoka

8

1 reference

Europe PubMed Central

PubMed publication ID

29 March 2018

http://europepmc.org/abstract/MED/24811212

Akio Osa

9

1 reference

Europe PubMed Central

PubMed publication ID

29 March 2018

http://europepmc.org/abstract/MED/24811212

Yuichiro Azuma

10

1 reference

Europe PubMed Central

PubMed publication ID

29 March 2018

http://europepmc.org/abstract/MED/24811212

Ichiro Kawase

11

1 reference

Europe PubMed Central

PubMed publication ID

29 March 2018

http://europepmc.org/abstract/MED/24811212

publication date

9 May 2014

1 reference

Europe PubMed Central

PubMed publication ID

29 March 2018

http://europepmc.org/abstract/MED/24811212

Asia Pacific Journal of Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

29 March 2018

http://europepmc.org/abstract/MED/24811212

11

1 reference

Europe PubMed Central

PubMed publication ID

29 March 2018

http://europepmc.org/abstract/MED/24811212

2

1 reference

Europe PubMed Central

PubMed publication ID

29 March 2018

http://europepmc.org/abstract/MED/24811212

121-128

1 reference

Europe PubMed Central

PubMed publication ID

29 March 2018

http://europepmc.org/abstract/MED/24811212

Detecting an overall survival benefit that is derived from progression-free survival

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12199

21 January 2018

Progression-free survival is a surrogate for survival in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12199

21 January 2018

Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12199

21 January 2018

Progression-free survival as a surrogate endpoint in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12199

21 January 2018

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12199

21 January 2018

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12199

21 January 2018

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12199

21 January 2018

Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12199

21 January 2018

Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12199

21 January 2018

A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12199

21 January 2018

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12199

21 January 2018

Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12199

21 January 2018

Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12199

21 January 2018

Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12199

21 January 2018

Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12199

21 January 2018

Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12199

21 January 2018

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12199

21 January 2018

Phase III trial comparing vinflunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12199

21 January 2018

Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12199

21 January 2018

Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12199

21 January 2018

Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12199

21 January 2018

A randomized phase II study of gefitinib plus simvastatin versus gefitinib alone in previously treated patients with advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12199

21 January 2018

Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12199

21 January 2018

Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12199

21 January 2018

Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12199

21 January 2018

Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12199

21 January 2018

Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12199

21 January 2018

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12199

21 January 2018

Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12199

21 January 2018

Randomized phase 2b study of pralatrexate versus erlotinib in patients with stage IIIB/IV non-small-cell lung cancer (NSCLC) after failure of prior platinum-based therapy

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12199

21 January 2018

Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12199

21 January 2018

Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12199

21 January 2018

Role of survival post-progression in phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer: a systematic review

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12199

21 January 2018

Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12199

21 January 2018

Time to progression as a surrogate marker for overall survival in patients with advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12199

21 January 2018

Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12199

21 January 2018

Issues in using progression-free survival when evaluating oncology products

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12199

21 January 2018

Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12199

21 January 2018

A Randomized Phase II Study of a Combination of Docetaxel and S-1 versus Docetaxel Monotherapy in Patients with Non-small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy: Results of Okayama Lung Cancer Study Group (OLCSG) Trial 0

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12199

21 January 2018

Identifiers

10.1111/AJCO.12199

1 reference

Europe PubMed Central

PubMed publication ID

29 March 2018

http://europepmc.org/abstract/MED/24811212

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 March 2018

http://europepmc.org/abstract/MED/24811212

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51088833&oldid=1244901914"